Crossmark

Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies

Crossref DOI link: https://doi.org/10.1186/s13195-022-01017-4

Published Online: 2022-05-28

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nguyen, Thi Ngoc Mai

Chen, Li-Ju

Trares, Kira

Stocker, Hannah

Holleczek, Bernd

Beyreuther, Konrad

Brenner, Hermann

Schöttker, Ben
Funding

Funding for this research was provided by:

Deutsches Krebsforschungszentrum (DKFZ)
License Information

Text and Data Mining valid from 2022-05-28

Version of Record valid from 2022-05-28
More Information

Article History

Received: 9 March 2022

Accepted: 12 May 2022

First Online: 28 May 2022

Declarations

:

: ESTHER was approved by the Ethics Committee of the Medical Faculty of the University of Heidelberg and Medical Association of Saarland (Application number: 58/2000). UK Biobank received ethical approval from the North West Multicentre Research Ethics Committee (REC reference: 11/NW/03820). Both ESTHER and UK Biobank are conducted in accordance with the 1964 Helsinki declaration and its later amendments. All study participants of the ESTHER study and UK Biobank gave written informed consent.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below